Floatz logo

Tinzaparin

Pancreatic Neoplasm

Helsinki University Central Hospitalother_biologicalPhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

376 Active assets in the Pancreatic Neoplasm cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Taiho Oncology, Inc.
Phase 3BB
Xaliplatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Fluorouracilum
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Tinzaparin is also rated in:

thrombotic diseaseActive
BB
Indicative · Phase 4
65 / 100
View asset →
venous thromboembolismActive
BB
Indicative · Phase 3
64 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →